

# A rare case of meningoencephalitis due to *Aspergillus fumigatus*

## Un raro caso di meningoencefalite causata da *Aspergillus fumigatus*

Cesare Bolla<sup>1</sup>, Tommaso Lupia<sup>2</sup>, Andrea Schimmenti<sup>1</sup>, Alberto Gaviraghi<sup>3</sup>, Serena Penpa<sup>1</sup>, Annalisa Roveta<sup>1</sup>, Francesco Giuseppe De Rosa<sup>2,3</sup>, Guido Chichino<sup>1</sup>, Antonio Maconi<sup>1</sup>

<sup>1</sup>Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria; <sup>2</sup>Infectious Diseases Unit, Cardinal Massaia Hospital, Asti; <sup>3</sup>Department of Medical Sciences, University of Turin; <sup>4</sup>Research Training Innovation Infrastructure, Research and Innovation Department, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

**Key words:** cerebral aspergillosis, immunocompetent, *Aspergillus*, fungi.

### ABSTRACT

Cerebral Aspergillosis (CA) is an opportunistic fungal infection that usually affects immunocompromised hosts. A man was admitted for loss of consciousness and aphasia. Computed Tomography (CT) scan showed a left cerebral frontal lesion. Nasal swab showed hyphae of *Aspergillus spp.*; isavuconazole was started. Lumbar Puncture (LP) tested positive for galactomannan (index 1.9), and *Aspergillus fumigatus* grew on the Cerebrospinal Fluid (CSF) culture. Unfortunately, a new episode of fever and a general deterioration then ensued up to the death. In immunocompetent patients as well, chronic fungal rhinosinusitis deserves attention due to its potential for rapid evolution to Central Nervous System (CNS) involvement.

L'Aspergillosi Cerebrale (CA) è un'infezione fungina opportunistica che colpisce principalmente gli individui immunocompromessi. In questo case report, riportiamo il caso di un uomo ricoverato per la comparsa improvvisa di perdita di coscienza e afasia. La Tomografia Computerizzata (TC) ha mostrato la presenza di una lesione cerebrale frontale sinistra. Successivamente, il tampone nasale ha rilevato la presenza di *Aspergillus spp.*; è stato pertanto avviato un trattamento con isavuconazolo. Ulteriori indagini hanno evidenziato alla puntura lombare (PL) la positività per il galattomannano (index 1.9) e l'isolamento di *Aspergillus fumigatus* nel liquido cerebrospinale (CSF). Nonostante l'inizio del trattamento, il paziente ha sviluppato nuovi episodi febbrili e ha manifestato un generale peggioramento delle condizioni cliniche fino alla morte. Il presente caso clinico sottolinea la necessità di un'attenta valutazione della rinosinusite fungina cronica anche nei pazienti immunocompetenti, data la potenziale rapida evoluzione verso il coinvolgimento del Sistema Nervoso Centrale (CNS).

### INTRODUCTION

*Aspergillus* is a ubiquitous opportunistic filamentous fungus that causes mold infections with a wide range of clinical syndromes in humans, and it may progress to Invasive Aspergillosis (IA). Most invasive infections are caused by members of the *A. fumigatus* species complex. In a report of 218 infections in 24 transplant centers in the United States, 67% were caused by members of the *A. fumigatus* complex, followed by *A. flavus* (13%), *A. niger* (9%), and *A. terreus* (7%). These data contrast with epidemiologic data from a decade earlier when the vast majority of cases (90%) were secondary to *A. fumigatus* species,<sup>1</sup> likely reflecting changes in microbial epidemiology, center-based differences, and/or changes in typing methods.

Emerging risk factors for patients with no or milder immunosuppression include: chronic obstructive pulmonary disease, with receipt of glucocorticoid therapy, Intensive Care Unit (ICU)

admission<sup>2</sup> and certain viral infections (e.g., influenza, Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2], respiratory syncytial virus).<sup>3</sup>

Cerebral Aspergillosis (CA) is a rare infection that occurs predominantly in previously healthy immunocompetent individuals. It is uncommon in seriously immunocompromised hosts, such as recipients of hematopoietic stem cell and solid organ transplants, patients with prolonged neutropenia, acquired immunodeficiency syndrome or haematologic malignancies, or persons undergoing treatments involving high doses of steroids.<sup>4</sup>

In a study of the Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI) findings associated with Central Nervous System (CNS) aspergillosis, three patterns were observed:<sup>5</sup> i) ring-enhancing lesions consistent with brain abscesses, ii) cerebral cortical and subcortical infarction with or without superimposed hematomas, iii) mucosal thickening of a paranasal sinus with secondary intracranial dural enhancement consistent with direct extension from the sinuses.

An increasing occurrence of CA is now being reported in immunocompetent patients who abuse cocaine by inhalation and especially in those who also have chronic rhinosinusitis.<sup>6,7</sup> The pathomorphosis of ventriculitis in these patients is more consistent with a cerebral aspergilloma than with ventriculitis secondary to an

intracranial abscess rupture. Early diagnosis is essential for proper treatment. In this report, we present a rare case of CA in an immunocompetent patient with a history of cocaine use.

## CASE REPORT

A 61-year-old male was admitted to the emergency department for loss of consciousness and aphasia. His Glasgow Coma Scale (GCS) score was 13 on admission. His past medical history included hypertension, non-insulin-dependent diabetes mellitus, a former smoking habit and occasional cocaine use by inhalation. A CT (Figure 1) scan showed a left cerebral frontal lesion and initial ventriculitis, which were confirmed by MRI. CSF obtained from a lumbar puncture showed 2,822 cells/mm<sup>3</sup> (90% polymorphonucleates), high proteinorrachia (345 g/dL) and hypoglycorrachia (67 g/dL; blood sugar 180 g/dL). Cefepime 2 g q8 hours plus metronidazole 500 mg q8 hours were empirically started, and blood and CSF were cultured. Serum and broncho-alveolar lavage results were negative for galactomannan, despite a positive serum result for beta-D-glucan (>500 pg/mL).

Due to neurological impairment and respiratory distress, the patient was admitted to the ICU and underwent endotracheal intubation. A surveillance nasal swab showed multiple hyphae of *Aspergillus* spp., raising the suspicion of possible CA; therefore, isavuconazole 372 mg q24h (after a loading dose of 372 mg q8h for six doses) was started. A new lumbar puncture tested positive for galactomannan (index 1.9; normal value 0.5), and colonies of *Aspergillus fumigatus* grew on the CSF culture (Figure 2).

The patient showed progressive clinical and radiological improvement, with recovery of consciousness, respiratory weaning, and reduction in the lesion size. Then isavuconazole was stopped after 20 days, and voriconazole was started.

The following CT scan showed a volumetric reduction of the known lesion, but it revealed hydrocephalus that required mechanical drainage. Subsequently, the patient suffered a spiking fever. Blood and urine were cultured but gave negative results. He was started on ceftazidime/avibactam and linezolid because of suspected post-procedure meningitis.

During the patient's hospitalization in the ICU, a rectal swab was positive for *Klebsiella pneumoniae* KPC. Because of his persistent hydrocephalus, the patient was referred to the Neurosurgical Unit for placement of an External Ventricular Drain (EVD). At that time, his GCS was 9/15. By 15 days after the procedure, he had severe neurological impairment (GCS 3/15), and MRI indicated cerebritis.

Amphotericin-B (liposomal) was added to the voriconazole, and the EVD was replaced upon observing a good response from the neurological aspect (GCS 14/15). Ceftazidime/avibactam and linezolid were stopped after 10 days of treatment. All the subsequent CSF cultures were negative.

A new episode of spiking fever followed by septic shock caused the rapid death of the patient.

## DISCUSSION

Although a rare event, CA can occur in immunocompetent patients and especially in those affected by chronic rhinosinusitis. The etiology remains unclear, but this condition usually occurs secondary to *Aspergillus* infection in tissues adjacent to the brain



Figure 1. Computed Tomography scan demonstrating a space-occupying lesion, approximately of 3,5 cm in diameter, localized in the left-posterior frontal lobe.




Figure 2. *Aspergillus fumigatus* culture (Sabouraud's dextrose agar) microscopic characteristics. A single series of phialides can be observed, giving origin to the rounded conidia disposed in long and parallel chains.

or through blood transmission. The most common cause of CNS aspergillosis is *Aspergillus* infection in the nasal sinuses, followed by dental and ear infections, contamination during cerebral or cardiac surgery, and lumbar puncture.<sup>8</sup>

Fungi may cause invasive fungal sinusitis that typically occurs in immunocompromised hosts and is rapidly progressive. Nevertheless, our clinical case showed that in immunocompetent patients as well, chronic fungal rhinosinusitis deserves particular attention due to its potential for rapid evolution to CNS involvement. CA is a life-threatening infection, but the prognosis is more favourable in immunocompetent than in immunocompromised patients.<sup>9</sup> However, CA is difficult to eradicate, and when these patients recover, they often have severe deficits and consequences.

## REFERENCES

- Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2002;34:909-17.
- Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. *Intensive Care Med*. 2012;38:1761-8.
- Thompson GR 3rd, Cornely OA, Pappas PG, et al. Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. *Open Forum Infect Dis*. 2020;7:ofaa242.
- Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;63:e1-e60.
- Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. *AJR Am J Roentgenol*. 1994;162: 155-9.
- Azulay-Abulafia L, Sousa MA, Pussanti A, et al. Invasive aspergillosis in a user of inhaled cocaine: rhinosinusitis with bone and cartilage destruction. *Rev Soc Bras Med Trop*. 2014; 47:533-6.
- Pekala KR, Clavenna MJ, Shockley R, et al. Chronic invasive fungal sinusitis associated with intranasal drug use. *Laryngoscope*. 2015;125:2656-9.
- Hersh CM, John S, Subei A, et al. Optic Neuropathy and Stroke Secondary to Invasive Aspergillus in an Immunocompetent Patient. *J Neuroophthalmol*. 2016;36:404-7.
- Ma Y, Li W, Ao R, et al. Central nervous system aspergillosis in immunocompetent patients: Case series and literature review. *Medicine (Baltimore)*. 2020;99:e22911.

Correspondence: Serena Penpa, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, via Venezia 16, 15121 Alessandria, Italy. Tel. 0131.206893. E-mail: serena.penpa@ospedale.al.it

Authors' contributions: TL, CB, AS, AG: substantial contributions to the concept of the paper, patient's data and follow-up collection, writing and original draft preparation; SP, AR: literature review, writing review and editing; FGDR, GC, AM: revision of the paper. All the authors have read and approved the final version of the manuscript and agreed to be held accountable for all aspects of the work.

Conflict of interest: the authors declare that there is no conflict of interest.

Funding: none.

Availability of data and materials: all data generated or analyzed during this study are included in this published article.

Received: 18 January 2023.

Accepted: 14 March 2023.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

*Working Paper of Public Health* 2023;11:9665

doi:10.4081/wpph.2023.9665

*This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).*